Intra-Cellular Therapies (ITCI) to Release Quarterly Earnings on Tuesday

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) will be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect Intra-Cellular Therapies to post earnings of ($0.31) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.14. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The company had revenue of $132.10 million for the quarter, compared to analysts' expectations of $135.97 million. During the same period last year, the firm earned ($0.45) earnings per share. Intra-Cellular Therapies's quarterly revenue was up 50.3% on a year-over-year basis. On average, analysts expect Intra-Cellular Therapies to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Intra-Cellular Therapies Stock Up 1.3 %

Intra-Cellular Therapies stock traded up $0.92 during midday trading on Wednesday, reaching $72.73. The company's stock had a trading volume of 714,820 shares, compared to its average volume of 930,365. Intra-Cellular Therapies has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The company has a market cap of $7.04 billion, a P/E ratio of -49.81 and a beta of 1.02. The business has a 50-day simple moving average of $69.22 and a 200-day simple moving average of $65.25.

Insider Activity

In related news, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the transaction, the executive vice president now directly owns 16,170 shares in the company, valued at approximately $1,076,275.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the transaction, the executive vice president now owns 16,170 shares of the company's stock, valued at approximately $1,076,275.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Sharon Mates sold 22,590 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $69.79, for a total value of $1,576,556.10. Following the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $73,301,065.11. The disclosure for this sale can be found here. In the last three months, insiders sold 168,487 shares of company stock worth $11,364,950. Company insiders own 3.40% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ITCI. TD Cowen raised their price objective on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday, April 17th. Needham & Company LLC raised their price target on Intra-Cellular Therapies from $82.00 to $90.00 and gave the stock a "buy" rating in a report on Monday, April 22nd. Cantor Fitzgerald reissued an "overweight" rating and set a $120.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 24th. The Goldman Sachs Group raised their price target on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a "neutral" rating in a report on Wednesday, April 17th. Finally, Mizuho raised their price target on Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a "buy" rating in a report on Monday, April 22nd. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $90.17.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.